These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 15282866)

  • 1. Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma.
    Dezube BJ; Aboulafia DM; Pantanowitz L
    AIDS Read; 2004 Jul; 14(7):372-4, 377-9. PubMed ID: 15282866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy.
    Talamo G; Angtuaco E; Walker RC; Dong L; Miceli MH; Zangari M; Tricot G; Barlogie B; Anaissie E
    J Clin Oncol; 2005 Aug; 23(22):5217-23. PubMed ID: 15955903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of newly diagnosed myeloma.
    Rajkumar SV; Palumbo A
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1141-56, ix-x. PubMed ID: 17996592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants.
    Jimenez-Zepeda VH; Heilman RL; Engel RA; Carey EJ; Freeman C; Rakela J; Mulligan DC; Fonseca R; Stewart AK
    Transplantation; 2011 Sep; 92(5):570-4. PubMed ID: 21712755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance.
    Kristinsson SY; Björkholm M; Schulman S; Landgren O
    Semin Hematol; 2011 Jan; 48(1):46-54. PubMed ID: 21232658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients.
    Amara S; Dezube BJ; Cooley TP; Pantanowitz L; Aboulafia DM
    Clin Infect Dis; 2006 Nov; 43(9):1198-205. PubMed ID: 17029142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma.
    Abdelkefi A; Torjman L; Ben Romdhane N; Ladeb S; El Omri H; Ben Othman T; Elloumi M; Bellaj H; Lakhal A; Jeddi R; Aissaouï L; Saad A; Hsaïri M; Boukef K; Dellagi K; Ben Abdeladhim A
    Bone Marrow Transplant; 2005 Aug; 36(3):193-8. PubMed ID: 15968290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients.
    Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fanin R
    Haematologica; 2003 May; 88(5):597-9. PubMed ID: 12745281
    [No Abstract]   [Full Text] [Related]  

  • 11. [Monoclonal gammopathy--multiple myeloma].
    Dietzfelbinger H
    MMW Fortschr Med; 2005 Jun; 147(24):32-3, 35-6. PubMed ID: 16001531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide-based treatment for HIV-associated multiple myeloma: a case report.
    Aboulafia DM
    AIDS Read; 2003 Aug; 13(8):383-9. PubMed ID: 14524324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide and dexamethasone: therapy for multiple myeloma.
    Kumar S; Rajkumar SV
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
    Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
    J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
    Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.